Trial ID or NCT#

NCT01946074

Status

not recruiting iconNOT RECRUITING

Purpose

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-165 when administered as monotherapy and in combination with paclitaxel or 5-fluoruracil, folinic acid and irinotecan (FOLFIRI) or ABBV-181 with/without paclitaxel in subjects with advanced solid tumors. Enrollment to Cohorts A, B, C and D is completed.

Official Title

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors

Eligibility Criteria

Ages Eligible for Study: 18 Years to 99 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

George W. Sledge Jr., M.D.
George W. Sledge Jr., M.D.
Medical oncologist, Breast specialist
Professor of Medicine (Oncology)
Melinda L. Telli, M.D.
Melinda L. Telli, M.D.
Medical oncologist, Breast specialist
Associate Professor of Medicine (Oncology)

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061